Zhitong Finance App News, Xiansheng Pharmaceutical (02096.HK) issued an announcement. On September 3, 2026, the Group's strategic cooperation with Ruiyang (Shandong) Biopharmaceutical Co., Ltd. (Ruiyang Biology) was approved by the China National Drug Administration (NMPA) to be marketed in China to prevent lower respiratory infections caused by RSV in newborns and infants with gestational age of at least 35 weeks during the first respiratory syncytial virus (RSV) epidemic season. Does not include chronic lung disease CLD includes children with bronchopulmonary abnormalities (BPD) or clinically significant congenital respiratory abnormalities. On August 20, 2026, the Group reached a strategic cooperation with Ruiyang Biotech and obtained the exclusive commercialization rights of Immule® in Greater China.

Zhitongcaijing · 3d ago
Zhitong Finance App News, Xiansheng Pharmaceutical (02096.HK) issued an announcement. On September 3, 2026, the Group's strategic cooperation with Ruiyang (Shandong) Biopharmaceutical Co., Ltd. (Ruiyang Biology) was approved by the China National Drug Administration (NMPA) to be marketed in China to prevent lower respiratory infections caused by RSV in newborns and infants with gestational age of at least 35 weeks during the first respiratory syncytial virus (RSV) epidemic season. Does not include chronic lung disease CLD includes children with bronchopulmonary abnormalities (BPD) or clinically significant congenital respiratory abnormalities. On August 20, 2026, the Group reached a strategic cooperation with Ruiyang Biotech and obtained the exclusive commercialization rights of Immule® in Greater China.